Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B)

View Full Paper
Ask AI
Bookmark
Share

Authors

RGRunxia GuKLKe LiSWShuning Wei

Discussion

Loading...

Member takes

Overview

Investigator-initiated trial demonstrates complete response in SLE-ITP patients following QT-019B therapy, suggesting new treatment for autoimmune disorders.

Key Points

  • Prompt normalization of platelet counts was achieved in patients with systemic lupus erythematosus-associated thrombocytopenia.
  • Among four patients completing DLT observation, three achieved a complete response with sustained improvements in platelet counts.
  • An allogeneic dual-target CAR T-cell therapy approach with QT-019B was used alongside lymphodepletion with fludarabine and cyclophosphamide.
  • The findings highlight the promise of QT-019B in treating autoimmune disorders, calling for further investigative trials.

Cite This Study

Gu et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e566https://doi.org/10.1182/blood-2025-3031
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and preliminary efficacy of a novel loop-optimized, BCMA/CD19 bispecific CAR-T therapy for refractory or relapsed autoimmune diseases patients2025
  2. 2One-year follow-up of CD19/BCMA dual-targeting fastcar-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus2025 · 1 citations
  3. 3Point of care anti-CD19 CAR-T for autoimmune diseases2025
  4. 4BCMA-targeted CAR T-cell therapy in refractory autoimmune diseases: Initial Results from a Phase 1 clinical trial2025 · 1 citations
  5. 5CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial2025 · 2 citations